CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 123 enrolled
Drug / intervention
Repetitive transcranial magnetic stimulationdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03378570
NCT03378570N/ACompleted
CompareCT.gov

The Effects of Repetitive Transcranial Magnetic Stimulation Prefrontal Target Location on Outcomes for Major Depressive Disorder

Nicholas Trapp·interventional·Posted Dec 20, 2017·Updated Feb 3, 2025

In Brief

A clinical study evaluating Repetitive transcranial magnetic stimulation for Major Depressive Disorder and Depression. Completed, enrolled 123 participants across 1 site.

Detailed Summary

The purpose of this study is to examine the effects of different treatment locations using repetitive transcranial magnetic stimulation (rTMS) to treat major depressive disorder.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder, Depression
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedDec 20, 2017
Enrollment StartMay 1, 2018
Primary CompletionSep 13, 2022
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 8.5 years ago

Interventions

Repetitive transcranial magnetic stimulationdevice

Repetitive transcranial magnetic stimulation will be targeted to a location in the left prefrontal cortex and delivered according to FDA-approved parameters for the treatment of major depressive disorder, specifically high-frequency 10 Hz rTMS for 3000 pulses, 5 days per week for a total number of sessions as deemed clinically appropriate by the patient's clinical TMS treatment team but usually on the order of 20-30 treatments.